United States: UK Supreme Court Rules On Validity And Infringement Of Second Medical Use Patents

On 14 November, the Supreme Court handed down its judgment on the validity and infringement of the second medical use patent that protected Pfizer's Lyrica® (pregabalin) for the treatment of various types of pain. In Warner-Lambert Company LLC v Generics (UK) Ltd (t/a Mylan) & Anor [2018] UKSC 56, the Court decided that the patent held by Warner-Lambert (a company in the Pfizer group) was invalid for insufficiency, because it did not render it plausible that pregabalin would be effective to treat all of the claimed types of pain. The Court also held that, had the claims been valid, they would not have been infringed by a "skinny label" generic version of pregabalin that had the protected indications carved out. However, the five judges of the Court were not in agreement on several key points.

Background to the case

Warner-Lambert's patent included claims to pain, inflammatory pain (caused by external stimuli) and neuropathic pain (caused by damage to the nervous system). The patent disclosed the results of three pre-clinical animal models used to test drugs for various kinds of pain, which demonstrated that pregabalin was effective in treating inflammatory pain; the parties disputed whether these results, together with the other material in the patent, rendered it plausible that pregabalin would also be effective to treat neuropathic pain (peripheral or central).

Pfizer Limited holds the marketing authorisation for Lyrica (pregabalin) for the treatment of both peripheral and central neuropathic pain, as well as epilepsy and GAD, these latter two indications no longer benefiting from any form of exclusivity. Issues have arisen as to the steps those obtaining authorisation of copy products should take to avoid infringement of the protected indications.

Actavis marketed a "skinny label" generic version of pregabalin, which included in its summary of product characteristics and patient information leaflet only the epilepsy and GAD indications. This is because the pain indications were "carved out" of the product information to avoid infringing Pfizer's patent. However, in 2014 Mylan and Actavis brought patent proceedings arguing that the claims of Warner-Lambert's patent that covered pain and neuropathic pain were invalid, and Actavis argued that, even if the claims were valid, the sale of its skinny label products did not infringe these claims.

Decisions of the Court

The dispute about the pregabalin patent has been long-running. In 2015, at first instance, Arnold J held the patent partially invalid for insufficiency and also held that, had the relevant claims been valid, they would not have been infringed. Following the trial, Warner-Lambert applied to amend its patent, to narrow its claim to neuropathic pain to cover only peripheral neuropathic pain, but this application was refused. In 2016, the Court of Appeal upheld Arnold J's decisions on amendment, construction and insufficiency; the Court of Appeal proposed a different test for infringement but, since the relevant claims of the patent were held to be invalid, nothing turned on this point.

The judgment of the Supreme Court, which was delayed a number of times, makes clear that the judges had different views on the various questions to be answered:

  • Amendment: The Court unanimously rejected Warner-Lambert's appeal against the refusal of its amendment. The Court held that a patentee's right to amend its patent under the European Patent Convention 2000 is subject to the national court's rules of procedure, and it maintained the Court of Appeal's application of the English procedural rules on post-trial amendments.
  • Construction: The Court upheld the decisions of the High Court and Court of Appeal on the construction of the "neuropathic pain" claim in the patent. Warner-Lambert had argued that this claim should be construed narrowly as referring only to peripheral neuropathic pain, in light of the description of the patent and applying a presumption that the court should prefer the construction that results in the claim being valid. However, the Court held that the claim (read in light of the description) should be construed broadly to cover all types of neuropathic pain and, as the claim was not ambiguous, there was no need to use the "validating principle" to prefer a narrower construction.
  • Sufficiency: Three of the five judges held that the material in Warner-Lambert's patent did not render it plausible that pregabalin would be effective to treat neuropathic pain generally, or peripheral neuropathic pain specifically. The judges said that in the context of a second medical use claim, the patent must disclose a "reasonable prospect" that the claimed compound would be effective in treating the claimed disease, and that this must be based on a "direct effect on a metabolic mechanism specifically involved in the disease". However, the two dissenting judges said that this requirement puts the test for sufficiency too high; they said that when applying the lower threshold, Warner-Lambert's patent contained enough material to make it plausible that pregabalin would be effective to treat peripheral neuropathic pain.
  • Infringement: While the Court found the patent claims to be invalid, the judges did comment on infringement. However, these comments are obiter and not binding in future cases. Four of the five judges held that Warner-Lambert's second medical use claims (if valid) would not have been infringed by the sale of skinny labelled product. However, they differed as to the reasons. Lord Reed and Lord Sumption held that the sole criterion for infringement is "whether the product as it emerges from the manufacturing process, including any labelling or accompanying leaflet, is presented as suitable for the uses which enjoy patent protection." Since the product information for the skinny labelled product only referred to the treatment of epilepsy and GAD, its sale would not infringe the pain patent. In contrast, Lord Hodge and Lord Briggs said that infringement depends on whether the alleged infringer subjectively intended to target the patent protected market which, on the facts, Actavis did not. Lord Mance took a different approach again, holding that the test depends on the objective appearance of the product but that (i) in rare cases, the context may make it obvious that this is not to be taken at face value, and (ii) there may be circumstances in which the generic manufacturer should positively exclude use for the patent-protected purpose. He declined to express a view on how that test would be applied in this case.


Whether a second medical use patent contains sufficient material to render it plausible that the claimed compound will be effective to treat the claimed disease will always be a highly fact-specific issue, dependent on the detailed information contained in the patent and the state of the common general knowledge at its priority date. However, in light of the difference of opinion between the Supreme Court judges, there will also be plenty of scope for future argument as to the legal principles and their correct application.

In relation to the Supreme Court's non-binding comments on infringement, the different tests proposed by the Court will lead to uncertainty for patent holders in the future, although it seems likely that it will be more difficult for patent holders to prove their second medical use patents have been infringed.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions